J 112534
Latest Information Update: 14 Sep 2004
At a glance
- Originator Banyu
- Class
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 31 Mar 2004 Banyu Pharmaceutical has become a wholly owned subsidiary of Merck & Co
- 10 Feb 2003 No development reported - Preclinical for Atherosclerosis in Japan (unspecified route)
- 27 Mar 2001 Preclinical development for Atherosclerosis in Japan (Unknown route)